Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Microprocessor-Controlled Prostheses for the Lower Limb | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Measurement of Serum Antibodies to Selected Biologic Agents | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Magnetic Resonance Imaging‐Guided Focused Ultrasound | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Lung Liquid Biopsy | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Long Term Acute Care Hospital (LTACH) Admission and Transition of Care Criteria, Effective 11/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Long Term Acute Care Hospital (LTACH) Admission and Transition of Care Criteria | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Local or Whole Body Hyperthermia | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Laser Treatment for Proliferative Vascular Lesions | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Laparoscopic, Percutaneous, and Transcervical Techniques for the Myolysis of Uterine Fibroids & Hysterectomies Effective 8-1-26 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Laparoscopic, Percutaneous, and Transcervical Techniques for the Myolysis of Uterine Fibroids & Hysterectomies | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Laboratory Tests Post Transplant and for Heart Failure | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Laboratory Testing Investigational Services | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Irreversible Electroporation (IRE) of Tumors Other Than Liver | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Invasive Prenatal (Fetal) Diagnostic Testing | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Infertility Services | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | In Vitro Chemoresistance and Chemosensitivity Assays | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Implantation of Intrastromal Corneal Ring Segments | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Identification of Microorganisms Using Nucleic Acid Probes | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Glucose Monitoring – Home - Non-One Touch Brand, Effective 10/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Glucose Monitoring – Continuous, Effective 10/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Glucose Monitoring - Home - Non-One Touch Brand | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Glucose Monitoring - Continuous | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Genetic Testing for Mitochondrial Disorders | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Genetic Testing for Epilepsy | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Genetic Testing for Duchenne and Becker Muscular Dystrophy | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Genetic Testing for Diagnosis and Management of Mental Health Conditions, Effective 11/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Genetic Testing for Diagnosis and Management of Mental Health Conditions | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Gene Expression Profiling for Cutaneous Melanoma | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management (New Title ProMark Risk Score), Effective 11/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Gender Affirming Care | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Expanded Fertility Services | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Exondys (eteplirsen) and Vyondys (golodirsen) for Duchenne Muscular Dystrophy | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Evaluation of Biomarkers for Alzheimer's Disease | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Epidural Injections for Pain Management, Effective 10/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Epidural Injections for Pain Management | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Digestive Enzyme Cartridges | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Dental Procedures in the Outpatient Setting | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Cryosurgical Ablation of Miscellaneous Solid Tumors other than Renal, Liver and Prostate | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Corneal Collagen Cross-linking | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies, Effective 9/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Catheter Ablation as Treatment for Atrial Fibrillation | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Bronchial Valves | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Blood Product Molecular Antigen Typing | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Biomarker Testing Mandate - Effective 9/1/2026 | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Biomarker Testing Mandate | New policy |
| Aug 2, 2026 | Blue Cross & Blue Shield of Rhode Island | Biomarker Testing in Risk Assessment and Management of Cardiovascular Disease | New policy |